Coronaviruses and influenza viruses pose a major risk to global health, underscored by the impact of the COVID-19 pandemic and continuing spread of SARS-CoV-2 variants.
The Duke CIVIC Vaccine Center (DCVC) hosted a hybrid annual retreat on May 4 and 5, the second retreat since the contract’s inception in September
The National Institute of Allergy and Infectious Diseases (NIAID) announced that the Duke Human Vaccine Institute (DHVI) has initiated enrollment of volunteers for a clinical
Florian Krammer, Principal Investigator of SEM-CIVIC, was elected to the 2023 Fellowship Class for the American Academy of Microbiology for his significant contributions to the field of microbiology.
The Pharmaceutical Society of Japan awarded Dr. Kristy Ainslie, of CIVR-HRP, the 2023 Sato Memorial International Award for her notable achievements in the field of pharmaceutical sciences.
Researchers from Duke CIVIC Vaccine Center (DCVC) developed an mRNA-lipid nanoparticle vaccine incorporating hemagglutinin antigens from 20 different influenza subtypes.
We interviewed the Principal Investigators responsible for leading each of the CIVICs Centers as part of a two-part interview series. Previously, we learned about the
CIVICs | Duke CIVICs Clinical Core | Principal Investigator Profile We interviewed the Principal Investigators (PIs) responsible for leading each of the CIVICs Centers as
The National Institute of Allergy and Infectious Diseases (NIAID) Collaborative Influenza Vaccine Innovation Centers (CIVICs) program is addressing critical gaps in the prevention and control of influenza
We interviewed the Principal Investigators responsible for leading each of the CIVICs Centers as part of a two-part interview series. Previously, we learned about the